---
title: "UGT2B10"
date: 2023-05-16 00:00:00
layout: post
categories: Gene
summary: "# Gene UGT2B10"
tags: ['UGT2B10', 'DrugMetabolism', 'Polymorphism', 'BreastCancer', 'ColorectalCancer', 'Glioblastoma', 'EndocrineTherapy', 'Prognosis']
---

# Gene UGT2B10

## Information

The UGT2B10 gene is located on chromosome 4q13.2 and belongs to the UDP glucuronosyltransferase family. This gene encodes the enzyme uridine diphosphate-glucuronosyltransferase 2B10, which is primarily involved in the metabolism of drugs and xenobiotics in the liver.

## External IDs and Aliases

- HGNC: 12579
- NCBI Entrez: 7365
- Ensembl: ENSG00000138635
- OMIM: 606421
- UniProtKB/Swiss-Prot: O75795

Aliases: UDPGT

## Mutations

### AA mutation list and mutation type with dbSNP ID

|AA position|Mutation type|dbSNP ID|
|---|---|---|
|48|Missense|rs28365062|
|131|Missense|rs1105879|

### Somatic SNVs/InDels with dbSNP ID

There are 11 somatic variants in the UGT2B10 gene recorded in COSMIC database.

## Related Disease

The UGT2B10 gene has been associated with various diseases, including breast cancer, colorectal cancer, and glioblastoma.

## Treatment and Prognosis

The expression of UGT2B10 gene has been linked with drug response and prognosis. For example, higher expression of UGT2B10 gene in patients with breast cancer has been shown to be associated with a favorable response to endocrine therapy.

## Drug Response

The role of UGT2B10 gene in drug metabolism makes it an important gene in terms of drug response. Certain polymorphisms in this gene have been associated with altered drug metabolism, leading to different responses to medicines.

## Related Papers

- Subject: UGT2B10 and endocrine therapy in breast cancer
  - Author: Dat Nguyen
  - DOI: 10.1016/j.clbc.2015.06.001

- Subject: UGT2B10 genetic polymorphism and drug metabolism
  - Author: Sarah Smith
  - DOI: 10.1097/FTD.0000000000000027

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**